Logo Image
|Webcasts|November 19, 2020

Clinical Development of Oncology Products in Japan – the 2nd Largest Market for Innovation

Author(s)IQVIA

*** Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST ***Japan, the second largest market for branded pharmaceuticals and innovation, is driven in part by Oncology with recent advances in genomic analysis technology. In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, and increased disease awareness, and identifiable patient populations, amongst other factors. ***On demand available after final airing until Nov. 19, 2021***

Register free: http://www.appliedclinicaltrialsonline.com/act_w/clinical_development

​Event Overview:
Japan is the second largest market for branded pharmaceuticals and innovation and continues to show strong year-on-year growth. Continuous investment in development in Japan is creating many opportunities and growing the potential for multinational biopharma companies.

This is driven in part by Oncology. With recent advances in genomic analysis technology, such as next generation sequencing (NGS), progress is being made in establishing genomic cancer medicine, whereby effective therapies are selected based on the results of genomic analysis of each individual patient.

In addition, the Japanese market is driven by ongoing regulatory and government initiatives that reward innovative product development. Such measures include accelerated review systems such as Sakigake and Conditional Early Approval. Other driving factors are related to shifts in population demographics leading to over 1 million cancer incidence in Japan each year.

Join IQVIA Japan as we discuss opportunities within the Japanese Oncology market and how you can take advantage to increase the value of your Oncology assets.

3 Key take-aways:

  • To obtain the information about the Oncology market in Japan
  • How to seize the opportunity in this strong potential market.
  • Overview and changes in the Japanese Regulatory Environment and international development strategy

Speaker: Alan Thomas, Director, Thought Leadership, IQVIA Japan Group

Time and Date: Thursday, November 19, 2020 | 4:00 pm-5:00 pm EST

On demand available after final airing until Nov. 19, 2021

Register free: http://www.appliedclinicaltrialsonline.com/act_w/clinical_development

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more